KLOW Quick Start
KLOW is a single co-formulated blend of four peptides: GHK-Cu, BPC-157, TB-500 and KPV. The first three are the same trio found in GLOW at the same 50/10/10 mg weights; KLOW adds 10 mg of KPV, an anti-inflammatory tripeptide derived from alpha-MSH. It is dosed as one product; the sections below break out what each component a given draw delivers.
This guide is an educational research reference. It does not diagnose, treat, or prescribe, and is not medical advice. Consult a licensed clinician before considering any compound.
KLOW Composition
Each KLOW vial contains 80 mg total. Like GLOW it is GHK-Cu-dominant by weight, with the three repair peptides each at 10 mg.
| Component | Vial content | Share | Primary research focus |
|---|---|---|---|
| GHK-Cu | 50 mg | 62.5% | Skin / collagen remodeling |
| BPC-157 | 10 mg | 12.5% | Angiogenesis; tendon / gut repair |
| TB-500 | 10 mg | 12.5% | Cell migration / soft tissue |
| KPV | 10 mg | 12.5% | Anti-inflammatory (α-MSH fragment) |
KLOW Dosing Protocol
KLOW is dosed as one product, once daily. Because it is a fixed blend, a single draw delivers all four components at the 5:1:1:1 ratio. The per-component amounts follow directly from the vial content and are shown below.
Injection — Subcutaneous
| Band | Per dose | Frequency |
|---|---|---|
| Low | 1.33 mg blend | Once daily |
| Reference | 2.67 mg blend | Once daily |
| High | 4 mg blend | Once daily |
Cycle guidelines
| Approach | Duration | Review point | Best for |
|---|---|---|---|
| Standard | 4–6 weeks | Week 4 | General research planning |
| Extended | 6–8 weeks | Week 6 | Slower tissue-remodeling endpoints |
Off periods of 2–4 weeks are common, partly to limit cumulative copper exposure from the GHK-Cu component.
KLOW Reconstitution Guide
KLOW ships as a lyophilized powder with a blue tint from the GHK-Cu component. A 3 mL reconstitution gives the tidy 300-unit division used throughout this site.
Injection
| BAC | Conc. | 2.67 mg dose |
|---|---|---|
| 3 mL | 26.7 mg/mL | 0.10 mL · 2.67 mg |
One reconstitution, one daily draw. Units are U-100 insulin-syringe units.
Per-unit component math
3 mL is 300 units, so each unit carries 1/300th of the vial: GHK-Cu 167 mcg, BPC-157 33.3 mcg, TB-500 33.3 mcg and KPV 33.3 mcg.
Reconstitution steps
- Inspect the vial. Confirm the label, expected milligram amount, and that the powder looks dry and intact.
- Wipe the stoppers. Use an alcohol swab on both the bacteriostatic water and peptide vial stoppers.
- Draw the chosen volume. 3 mL into the vial — this is the number that sets every concentration figure above.
- Inject down the wall. Release the water slowly down the inside wall, not directly onto the powder.
- Swirl, do not shake. Roll gently until dissolved. Shaking foams and can damage the peptide.
- Verify clarity. A blue tint from GHK-Cu is expected. The solution should still be clear rather than cloudy; discard if particulate.
- Label and refrigerate. Note the date and volume added on the vial, then store at 2–8 °C. Do not freeze the reconstituted solution.
See the bacteriostatic water guide for diluent handling, or the reconstitution calculator to work any other volume.
Why These Four Together
KLOW extends the GLOW rationale with a fourth mechanism. GHK-Cu drives collagen and matrix remodeling, BPC-157 supports angiogenesis, and TB-500 supports cell migration — the same complementary trio. KPV, the C-terminal tripeptide of alpha-MSH, adds a distinct anti-inflammatory arm: it retains the anti-inflammatory activity of the parent hormone without its pigmentary effects, and is reported to act intracellularly on NF-κB signalling.
GHK-Cu
Collagen and matrix remodeling; dominant by weight.
BPC-157
Angiogenesis and gut/vessel repair signalling.
TB-500
Actin-mediated cell migration into injured tissue.
KPV
Anti-inflammatory α-MSH fragment; reported NF-κB modulation without pigmentary activity.
Who Should Avoid KLOW
The blend inherits every caution that applies to its four components, so the exclusions are the union of all of them.
Tested athletes
TB-500 and BPC-157 are both on the WADA Prohibited List; the blend is therefore prohibited in sport.
Active or prior cancer
Angiogenic and proliferative pathways across several components are a theoretical concern.
Copper-metabolism disorders
GHK-Cu contributes copper at 50 mg per vial; avoid in Wilson's disease.
Pregnancy & lactation
No human safety data for any component in this context.
KLOW Side Effects & Safety
Injection-site reactions
Redness or stinging; the GHK-Cu component can sting more than the others. Rotate sites.
Combined profile
Effects reflect all four components — review each component page rather than treating the blend as one entity.
Copper exposure
GHK-Cu-dominant, so cumulative copper applies; off-periods are the usual mitigation.
Quality-control risk
A four-peptide blend is the hardest kind of product to verify visually — check per-component purity on the COA.
KLOW Evidence Context
Component-level literature
Each of the four has its own preclinical base; GHK-Cu and BPC-157 are the best characterised.
KPV research
Studied largely in gastrointestinal inflammation models, often via oral or topical routes.
Blend data
No dedicated human trial exists for this four-component combination.
Open question
Whether four simultaneous mechanisms outperform the three in GLOW is untested.
Storage & Handling
| State | Storage | Notes |
|---|---|---|
| Lyophilized (powder) | −20 °C, protected from light | Blue tint from GHK-Cu is normal. |
| Reconstituted (liquid) | 2–8 °C | Use within ~30 days per the listing; do not freeze. |
| Appearance | Clear blue solution | Discard cloudy or particulate solutions. |
KLOW vs GLOW
| Feature | KLOW | GLOW |
|---|---|---|
| Components | GHK-Cu, BPC-157, TB-500, KPV | GHK-Cu, BPC-157, TB-500 |
| Total content | 80 mg (50/10/10/10) | 70 mg (50/10/10) |
| Ratio | 5 : 1 : 1 : 1 | 5 : 1 : 1 |
| Added arm | KPV anti-inflammatory | None |
| Page | This page | GLOW |
Frequently Asked Questions
What is in KLOW?
Four co-formulated peptides in one 80 mg vial: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg and KPV 10 mg.
How does it differ from GLOW?
KLOW is GLOW plus 10 mg of KPV, an anti-inflammatory alpha-MSH fragment. The other three components are at identical weights. See GLOW.
How much of each compound does a dose deliver?
At the 2.67 mg reference band (10 units of a 3 mL reconstitution): GHK-Cu 1.67 mg, BPC-157 0.33 mg, TB-500 0.33 mg and KPV 0.33 mg.
What is KPV?
The C-terminal tripeptide of alpha-MSH (Lys-Pro-Val). It retains the anti-inflammatory activity of the parent hormone without its pigmentary effects, and is reported to act on NF-κB signalling.
How is it reconstituted?
80 mg in 3 mL of bacteriostatic water gives 26.7 mg/mL. Because 3 mL is 300 units, each unit carries 1/300th of the vial.
Is this page medical advice?
No. It is an educational research reference and does not diagnose, treat, or prescribe. Consult a licensed clinician before considering any compound.
KLOW Formats & Sourcing
KLOW is supplied as a lyophilized powder in a single 80 mg vial. There is no pre-reconstituted pen or spray format for this blend. Batch-specific Certificates of Analysis are issued per lot, covering each of the four components.
| Format | Supplied as |
|---|---|
| Vial | 80 mg total lyophilized blend |
Strengths are listed as sold; confirm against the product page and the batch COA before calculating anything.
Reference material for this protocol, with batch COA:
View KLOW on Spyro Peptides →References
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide. Int J Mol Sci (2018).
- Sikiric P, et al. Stable gastric pentadecapeptide BPC 157. Curr Pharm Des (2011).
- Goldstein AL, et al. Thymosin β4: actin-sequestering protein and tissue repair. Ann N Y Acad Sci (2012).
- Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology (2008).
- Component-level dosing references are compiled on the linked GHK-Cu, BPC-157 and TB-500 pages.